BioAlliance Pharma SA, of Paris, said the European Independent Board of Experts held its first meeting on the ReLive Phase III trial evaluating the efficacy of Livatag (doxorubicin Transdrug) in primary liver cancer and recommended continuing the global, multicenter, randomized study without modification. (See BioWorld International, June 29, 2011

What we have counted is all clinical milestones up to and including approval," Claus Kremoser, CEO of Ludwigshafen, Germany-based Phenex told BioWorld International

It will cover half of the budget for next year," Thomas von Rüden, an angel investor who is acting as a business advisor to the company, told BioWorld International

In the body, almost any cell can eat other cells," Kodi Ravichandran told BioWorld International

The Abd Serotec unit comprises three main components: the company's in-house research antibody business, Antibodies by Design, along with Biogenesis Ltd., of Poole, UK, which MorphoSys acquired in 2005 for £5.25 million (US$8.5 million), and Oxford, UK-based Serotec Ltd., which it acquired for €29.3 million in cash and shares in 2006. (See BioWorld International, Jan. 16, 2006.) Revenues for the business peaked at €20.2 million in 2010 but dropped to €19.3 million in 2011 and looked likely to

The 10-year market exclusivity starts ticking from the formal commission decision," Biotie CEO Timo Veromaa told BioWorld International...The company disclosed last week that its Parkinson's disease drug tozadenant (SYN115), which it is co-developing with UCB SA, of Brussels, Belgium, hit the primary endpoint of a Phase IIb trial. (See BioWorld International, Dec. 12, 2012.)

We've worked hard to reposition and find another partner, and this is a validation of that effort," Polywka told BioWorld International...Roche had options to buy back the compounds, but decided against doing so in May 2011, after Evotec terminated a Phase II proof-of-concept trial of lead product EVT 101 in treatment-resistant depression because of difficulties in recruiting patients. (See BioWorld International, May 25, 2011.) That decision cost Evotec $65 million due if Roche had exercised the

What we have counted is all clinical milestones up to and including approval," Claus Kremoser, CEO of Ludwigshafen, Germany-based Phenex told BioWorld International

The Abd Serotec unit comprises three main components: the company's in-house research antibody business, Antibodies by Design, along with Biogenesis Ltd., of Poole, UK, which MorphoSys acquired in 2005 for £5.25 million (US$8.5 million), and Oxford, UK-based Serotec Ltd., which it acquired for €29.3 million in cash and shares in 2006. (See BioWorld International, Jan. 16, 2006.) Revenues for the business peaked at €20.2 million in 2010 but dropped to €19.3 million in 2011 and looked likely to

Roche had options to buy back the compounds, but decided against doing so in May 2011, after Evotec terminated a Phase II proof-of-concept trial of lead product EVT 101 in treatment-resistant depression because of difficulties in recruiting patients. (See BioWorld International, May 25, 2011.) That decision cost Evotec $65 million due if Roche had exercised the right to take EVT 101 back in-house, plus a further $225 million in development and commercial milestones if the product had made it to

The company disclosed last Tuesday that its Parkinson's disease drug tozadenant (SYN115), which it is co-developing with UCB SA, of Brussels, Belgium, hit the primary endpoint of a Phase IIb trial. (See BioWorld International, Dec. 12, 2012.)

Roche had options to buy back the compounds, but decided against doing so in May 2011, after Evotec terminated a Phase II proof-of-concept trial of lead product EVT 101 in treatment-resistant depression because of difficulties in recruiting patients. (See BioWorld International, May 25, 2011.) That decision cost Evotec $65 million due if Roche had exercised the right to take EVT 101 back in-house, plus a further $225 million in development and commercial milestones if the product had made it to

Life sciences is what has provided most of the returns at Sofinnova over a long period of time, across all of the funds," managing partner, Antoine Papiernik, told BioWorld International

43 percent is a good signal," Olav Hellebø, CEO of Oslo, Norway-based Clavis told BioWorld International

Andy Burrows, director of investor relations at BTG, told BioWorld International that analysts are predicting "at least a $500 million increase in sales" as a result of the label extensions in the U.S

The tax breaks on offer would attract money from a swath of midrange earners at a time when low interest rates mean returns on traditional savings and investment instruments have hit rock bottom, the BIA said. (See BioWorld International, Sept. 5, 2012.) Stephen Whitehead, chief executive of the Association of the British Pharmaceutical Industry, echoed Bates' assessment, saying a lot more needs to be done to maintain the UK's standing as an attractive place for pharma companies to operate

The decrease associated with tozadenant was "clinically relevant and statistically highly significant," Biotie CEO Timo Veromaa told BioWorld International

Life sciences is what has provided most of the returns at Sofinnova over a long period of time, across all of the funds," managing partner, Antoine Papiernik, told BioWorld International

Panos Deloukas, senior group leader in the department of human genetics at the Wellcome Trust Sanger Institute, told BioWorld International: "We have found new genetic risk factors for CAD